Median cost of insulin products in the U.S. calculated as AWP (62) and NADAC (63) per 1,000 units of specified dosage form/product
| Insulins . | Compounds . | Dosage form/product . | Median AWP (min, max)* . | Median NADAC* . |
|---|---|---|---|---|
| Rapid-acting | • Lispro follow-on product | U-100 vial | $157 | $125 |
| U-100 prefilled pen | $202 | $161 | ||
| • Lispro | U-100 vial | $165† | $132† | |
| U-100 cartridges | $408 | $326 | ||
| U-100 prefilled pen | $212† | $170† | ||
| U-200 prefilled pen | $424 | $339 | ||
| • Lispro-aabc | U-100 vial | $330 | N/A | |
| U-100 prefilled pen | $424 | N/A | ||
| U-200 prefilled pen | $424 | N/A | ||
| • Glulisine | U-100 vial | $341 | $272 | |
| U-100 prefilled pen | $439 | $350 | ||
| • Aspart | U-100 vial | $174† | $139† | |
| U-100 cartridges | $215 | $344 | ||
| U-100 prefilled pen | $223† | $179† | ||
| • Aspart (“faster acting product”) | U-100 vial | $347 | $278 | |
| U-100 cartridge | $430 | N/A | ||
| U-100 prefilled pen | $447 | $356 | ||
| • Inhaled insulin | Inhalation cartridges | $924 | $606 | |
| Short-acting | • human regular | U-100 vial | $165†† | $133†† |
| Intermediate-acting | • human NPH | U-100 vial | $165†† | $133†† |
| U-100 prefilled pen | $208 | $167 | ||
| Concentrated human regular insulin | • U-500 human regular insulin | U-500 vial | $178 | $143 |
| U-500 prefilled pen | $229 | $183 | ||
| Long-acting | • Glargine follow-on product | U-100 prefilled pen | $190 (118, 261) | $210 |
| U-100 vial | $190 (118, 261) | N/A | ||
| • Glargine | U-100 vial; U-100 prefilled pen | $340 | $272 | |
| U-300 prefilled pen | $340 | $272 | ||
| • Detemir | U-100 vial; U-100 prefilled pen | $370 | $296 | |
| • Degludec | U-100 vial; U-100 prefilled pen; U-200 prefilled pen | $407 | $325 | |
| Premixed insulin products | • NPH/regular 70/30 | U-100 vial | $165†† | $133†† |
| U-100 prefilled pen | $208 | $167 | ||
| • Lispro 50/50 | U-100 vial | $342 | $273 | |
| U-100 prefilled pen | $424 | $338 | ||
| • Lispro 75/25 | U-100 vial | $342 | $274 | |
| U-100 prefilled pen | $212 | $340 | ||
| • Aspart 70/30 | U-100 vial | $180 | $144 | |
| U-100 prefilled pen | $224 | $179 | ||
| Premixed insulin/GLP-1 RA products | • Glargine/Lixisenatide | 100/33 prefilled pen | $589 | $471 |
| • Degludec/Liraglutide | 100/3.6 prefilled pen | $874 | $701 |
| Insulins . | Compounds . | Dosage form/product . | Median AWP (min, max)* . | Median NADAC* . |
|---|---|---|---|---|
| Rapid-acting | • Lispro follow-on product | U-100 vial | $157 | $125 |
| U-100 prefilled pen | $202 | $161 | ||
| • Lispro | U-100 vial | $165† | $132† | |
| U-100 cartridges | $408 | $326 | ||
| U-100 prefilled pen | $212† | $170† | ||
| U-200 prefilled pen | $424 | $339 | ||
| • Lispro-aabc | U-100 vial | $330 | N/A | |
| U-100 prefilled pen | $424 | N/A | ||
| U-200 prefilled pen | $424 | N/A | ||
| • Glulisine | U-100 vial | $341 | $272 | |
| U-100 prefilled pen | $439 | $350 | ||
| • Aspart | U-100 vial | $174† | $139† | |
| U-100 cartridges | $215 | $344 | ||
| U-100 prefilled pen | $223† | $179† | ||
| • Aspart (“faster acting product”) | U-100 vial | $347 | $278 | |
| U-100 cartridge | $430 | N/A | ||
| U-100 prefilled pen | $447 | $356 | ||
| • Inhaled insulin | Inhalation cartridges | $924 | $606 | |
| Short-acting | • human regular | U-100 vial | $165†† | $133†† |
| Intermediate-acting | • human NPH | U-100 vial | $165†† | $133†† |
| U-100 prefilled pen | $208 | $167 | ||
| Concentrated human regular insulin | • U-500 human regular insulin | U-500 vial | $178 | $143 |
| U-500 prefilled pen | $229 | $183 | ||
| Long-acting | • Glargine follow-on product | U-100 prefilled pen | $190 (118, 261) | $210 |
| U-100 vial | $190 (118, 261) | N/A | ||
| • Glargine | U-100 vial; U-100 prefilled pen | $340 | $272 | |
| U-300 prefilled pen | $340 | $272 | ||
| • Detemir | U-100 vial; U-100 prefilled pen | $370 | $296 | |
| • Degludec | U-100 vial; U-100 prefilled pen; U-200 prefilled pen | $407 | $325 | |
| Premixed insulin products | • NPH/regular 70/30 | U-100 vial | $165†† | $133†† |
| U-100 prefilled pen | $208 | $167 | ||
| • Lispro 50/50 | U-100 vial | $342 | $273 | |
| U-100 prefilled pen | $424 | $338 | ||
| • Lispro 75/25 | U-100 vial | $342 | $274 | |
| U-100 prefilled pen | $212 | $340 | ||
| • Aspart 70/30 | U-100 vial | $180 | $144 | |
| U-100 prefilled pen | $224 | $179 | ||
| Premixed insulin/GLP-1 RA products | • Glargine/Lixisenatide | 100/33 prefilled pen | $589 | $471 |
| • Degludec/Liraglutide | 100/3.6 prefilled pen | $874 | $701 |
AWP, average wholesale price; GLP-1 RA, glucagon-like peptide 1 receptor agonist; N/A, not available; NADAC, National Average Drug Acquisition Cost.
AWP or NADAC calculated as in Table 9.2.
Generic prices used when available.
AWP and NADAC data presented do not include vials of regular human insulin and NPH available at Walmart for approximately $25/vial; median listed alone when only one product and/or price.